@article{8c808271ecba47bfab11172ffd384e1f,
title = "Realizing value with proprotein convertase subtilisin/kexin type 9 inhibitors are we closer to finding the sweet spot?",
keywords = "Editorials, Lipids",
author = "Blumenthal, {Roger S.} and Khurram Nasir and Martin, {Seth S.}",
note = "Funding Information: Dr Martin reports receiving personal fees for serving on scientific advisory boards for Amgen, Sanofi/Regeneron, Quest Diagnostics, and Akcea Therapeutics, as well as grants and research support from the PJ Schafer Cardiovascular Research Fund, the David and June Trone Family Foundation, American Heart Association, Aetna Foundation, Maryland Innovation Initiative, Nokia, iHealth, Google, and Apple outside the submitted work. In addition, Dr Martin reports having patent applications pending.",
year = "2018",
doi = "10.1161/CIRCULATIONAHA.118.035156",
language = "English (US)",
volume = "138",
pages = "767--769",
journal = "Circulation",
issn = "0009-7322",
publisher = "Lippincott Williams and Wilkins",
number = "8",
}